- BNF:
- Not listed
- Status:
- Red
- Decision Date:
- November 2016
Comments
RED: NICE TA653 for treating EGFR T790M mutation-positive locally advanced or metastatic NSCLC. (Decision date - November 2020)
RED: NICE TA654 for untreated EGFR mutation-positive NSCLC. (Replaces TA621). (Decision date - November 2020)
RED: NICE TA1043: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (decision date March 25)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
